MYRBETRIQ GRANULES (Mirabegron) Patent Expiration, LOE Window & CMS Spending

MYRBETRIQ GRANULES (Mirabegron) by Astellas Pharma: FDA Orange Book core substance LOE 2036-09-30, 1 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN213801 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-09-30
Last Listed Patent or Exclusivity Date2036-09-30
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.